TARGETED MRNA CLEAVAGE BY 3 TRNASE AND SMALL GUIDE RNAS
TARGETED MRNA CLEAVAGE BY 3 TRNASE AND SMALL GUIDE RNAS
批准号:
2605397
负责人:
ROGER L KASPAR
金额:
$11.1万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-09-01 至 2001-08-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Antisense and ribozyme methodologies show great promise for inhibiting
inappropriate gene expression and ultimately treating various disease
states. Unfortunately, these approaches have several drawbacks
including difficulty in delivering the nucleic acid to the cell whether
by gene therapy or oligonucleotide methods.
Oligonucleotides containing as few as seven nucleotides are effective
in targeting specific RNAs for cleavage in vitro by a 3' RNase found in
all mammalian cells. This cleavage requires that the oligonucleotide
(small guide RNA) hybridize at a precise distance from particular
secondary structures. This technique has successfully targeted HIV RNAs
for cleavage in vitro. The goal of this proposal is to show that mRNAs
can be specifically targeted for cleavage in vitro as well as in vivo.
The specific aims of the project are to: 1) show that this method can
be used to specifically target functional mRNAs including
chloramphenicol acetyl transferase (CAT) in vitro, 2) structure map the
resulting CAT mRNA/small guide RNA hybrids to investigate whether the
proposed computer-generated structures actually form in vitro, and 3)
introduce RNA heptamers and/or constructs expressing short RNA molecules
which hybridize to reporter mRNAs (e.g CAT), to determine the efficiency
of endogenous 3' tRNase to specifically degrade targeted mRNAs in vivo.
This approach has many advantages over other oligonucleotide-based
methods for modulating inappropriate gene expression in a clinical
situation since oligonucleotides containing only seven nucleotides
appear to be efficacious in contrast to traditional antisense approaches
in which nucleotides containing greater than 15-20 nucleotides are
required. Smaller oligonucleotides are much more easily taken up by the
cell, may be more resistant to degradation, and are more easily
chemically modified to increase their stability and cell membrane
permeability.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
The inhibitory effect of the autoantigen La on in vitro 3' processing of mammalian precursor tRNAs.
自身抗原 La 对哺乳动物前体 tRNA 体外 3 加工的抑制作用。
DOI:
10.1006/jmbi.2001.5026
发表时间:
2001
期刊:
Journal of molecular biology.
影响因子:
--
作者:
[Nashimoto,M, Nashimoto,C, Tamura,M, Kaspar,RL, Ochi,K]
通讯作者:
Ochi,K
Topical sirolimus Phase 1b trial for pachyonychia congenita (IND number 117347)
-
批准号:8950761
-
项目类别:
-
资助金额:$19.94万
-
财政年份:2015
-
负责人:ROGER L KASPAR
-
依托单位:
Development of topical formulations for delivery of next generation mTOR inhibito
-
批准号:8782436
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:ROGER L KASPAR
-
依托单位:
Evaluation of siRNA uptake and functional activity in a human organotypic skin mo
-
批准号:7915054
-
项目类别:
-
资助金额:$34.09万
-
财政年份:2010
-
负责人:ROGER L KASPAR
-
依托单位:
Pachyonychia congenita clinical trial using therapeutic siRNAs
-
批准号:7539266
-
项目类别:
-
资助金额:$31.27万
-
财政年份:2008
-
负责人:ROGER L KASPAR
-
依托单位:
Pachyonychia congenita clinical trial using therapeutic self-delivery siRNAs
-
批准号:8203881
-
项目类别:
-
资助金额:$208.8万
-
财政年份:2008
-
负责人:ROGER L KASPAR
-
依托单位:
Pachyonychia congenita clinical trial using therapeutic self-delivery siRNAs
-
批准号:8336922
-
项目类别:
-
资助金额:$97.34万
-
财政年份:2008
-
负责人:ROGER L KASPAR
-
依托单位:
In vivo imaging models for evaluating siRNA delivery to skin
-
批准号:7405503
-
项目类别:
-
资助金额:$14.82万
-
财政年份:2008
-
负责人:ROGER L KASPAR
-
依托单位:
Development of topical rapamycin as a novel treatment for skin disorders
-
批准号:7481638
-
项目类别:
-
资助金额:$22.63万
-
财政年份:2008
-
负责人:ROGER L KASPAR
-
依托单位:
Pachyonychia congenita clinical trial using therapeutic self-delivery siRNAs
-
批准号:8530953
-
项目类别:
-
资助金额:$104.58万
-
财政年份:2008
-
负责人:ROGER L KASPAR
-
依托单位:
Development of RNA-based topical psoriasis inhibitors
-
批准号:6935527
-
项目类别:
-
资助金额:$28.59万
-
财政年份:2005
-
负责人:ROGER L KASPAR
-
依托单位:
Development of siRNA libraries for antiviral discovery
-
批准号:6789086
-
项目类别:
-
资助金额:$29.47万
-
财政年份:2004
-
负责人:ROGER L KASPAR
-
依托单位:
Redirection of Fas splicing as a cancer therapy
-
批准号:6934816
-
项目类别:
-
资助金额:$2.27万
-
财政年份:2003
-
负责人:ROGER L KASPAR
-
依托单位:
Inhibition of hepatitis C by RNA Lassos
-
批准号:6784661
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2003
-
负责人:ROGER L KASPAR
-
依托单位:
Redirection of Fas splicing as a cancer therapy
-
批准号:6691155
-
项目类别:
-
资助金额:$29.2万
-
财政年份:2003
-
负责人:ROGER L KASPAR
-
依托单位:
Inhibition of hepatitis C by RNA Lassos
-
批准号:6690614
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2003
-
负责人:ROGER L KASPAR
-
依托单位:
海外基金